Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Acute Myeloid Leukemia (AML)
August 12, 2020In the last three years, there have been eight new drugs approved for AML in the US, dramatically changing the treatment landscape. Gone is the era where all front-line patients received 7+3 chemotherapy or a hypomethylating agent (decitabine or azacitidine). Many of the new therapies target specific segments of AML or patients with specific mutations. As such, there is currently little competition between the new therapies, but that will change as therapies receive label expansions and new competitor therapies are approved.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Acute Myelogenous Leukemia (AML)|